RIG-I-targeted immunotherapy synergizes with immune checkpoint inhibition in a hepatocellular carcinoma model
Authors:
- Charlotte MarxCMCharlotte Marx
- Julia TeppertJTJulia Teppert
- Laura MarischLMLaura Marisch
- Simone FormisanoSFSimone Formisano
- Anne SenzASAnne Senz
- Daniel F R. BoehmerDBDaniel F R. Boehmer
- Philipp MetzgerPMPhilipp Metzger
- Daryna KechurDKDaryna Kechur
- Luisa DeliusLDLuisa Delius
- Christine HoerthCHChristine Hoerth
- Kirsten LauberKLKirsten Lauber
- Doris MayrDMDoris Mayr
- 25 June 2026
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- p. OF1-OF14
Abstract
Retinoic acid-inducible gene-I (RIG-I) is a cytoplasmic pattern recognition receptor that senses short double-stranded RNA with uncapped 5’-triphosphate (3p-RNA). Upon activation, RIG-I induces type I interferons and proinflammatory cytokines, thereby promoting adaptive immunity. Thus, RIG-I activation is a promising approach for creating a proinflammatory tumor microenvironment. In this study, we investigated its therapeutic potential in hepatocellular carcinoma (HCC). We explored and confirmed RIG-I expression and signaling in human HCC samples and cell lines. The therapeutic potential of RIG-I activation by 3p-RNA for the treatment of HCC was investigated in vitro and in syngeneic murine orthotopic tumor models. In vivo, 3p-RNA treatment significantly reduced the tumor burden, delayed disease progression, and achieved partial complete remission of RIL-175 tumors with durable immune memory. However, no therapeutic effects were observed in the Hep-55.1C model. Tumor clearance depended on CD4⁺ and CD8⁺ T cells, but not NK cells. Additionally, 3p-RNA induced PD-L1 expression on HCC cells, enhancing their sensitivity to anti-PD-1 immune checkpoint therapy in vivo. RIG-I activation via 3p-RNA therapy shows promise as an immunotherapeutic strategy for hepatocellular carcinoma (HCC). Future investigations need to focus on tumor-intrinsic factors to understand heterogeneity between tumors and to overcome resistance mechanisms.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (224057855)
- Deutsche Forschungsgemeinschaft (329628492-SFB 1321)
- Deutsche Forschungsgemeinschaft (391217598)
- Agence Nationale de la Recherche (ANR-17-CE15-0031-01)
- Horizon 2020 Framework Programme (101137459)
- HORIZON EUROPE Marie Sklodowska-Curie Actions (641549)
- Elitenetzwerk Bayern
- Elitenetzwerk Bayern
- Else Kröner-Fresenius-Stiftung (2023_EKEA.60)
- Ludwig-Maximilians-Universität München
- Deutsche Forschungsgemeinschaft (442265435)
- Deutsche Forschungsgemeinschaft (369799452-TRR 237)